Inventor · disambiguated record
Edward Cleator
Also filed as: CLEATOR EDWARD
19 granted patents·7 pending applications·105 citations·filing 2006–2023
94Inventor score
Files withMERCK SHARP & DOHME15JANSSEN PHARMACEUTICA NV3INTERVET INC2ARROWHEAD PHARMACEUTICALS INC1ASHWOOD MICHAEL STEWART1
Top patents by PatentIndex Score
26 records- 0196US11124478B2Process for making beta 3 agonists and intermediatesMERCK SHARP & DOHME·Filed 2020·Granted Sep 21, 2021·5 cites·5 claims
- 0295US11767292B2Process for making beta 3 agonists and intermediatesMERCK SHARP & DOHME·Filed 2021·Granted Sep 26, 2023·3 cites·12 claims
- 0395US11708371B2Process for making beta 3 agonists and intermediatesMERCK SHARP & DOHME·Filed 2021·Granted Jul 25, 2023·3 cites·13 claims
- 0495US10899771B2Process for making beta 3 agonists and intermediatesMERCK SHARP & DOHME·Filed 2019·Granted Jan 26, 2021·7 cites·4 claims
- 0595US10577316B2Process for making beta 3 agonists and intermediatesMERCK SHARP & DOHME·Filed 2017·Granted Mar 3, 2020·9 cites·23 claims
- 0694US9822121B2Process for making beta 3 agonists and intermediatesMERCK SHARP & DOHME·Filed 2016·Granted Nov 21, 2017·13 cites·12 claims
- 0794US9809536B2Process for making beta 3 agonists and intermediatesMERCK SHARP & DOHME·Filed 2012·Granted Nov 7, 2017·12 cites·19 claims
- 0894US9487523B2Process for making CGRP receptor antagonistsMERCK SHARP & DOHME·Filed 2013·Granted Nov 8, 2016·17 cites·19 claims
- 0993US10435410B2Process for making beta 3 agonists and intermediatesMERCK SHARP & DOHME·Filed 2018·Granted Oct 8, 2019·9 cites·16 claims
- 1093US10087189B2Process for making beta 3 agonists and intermediatesMERCK SHARP & DOHME·Filed 2017·Granted Oct 2, 2018·10 cites·10 claims
- 1187US9073825B2Methods and intermediates for preparing macrolactamsYASUDA NOBUYOSHI·Filed 2012·Granted Jul 7, 2015·8 cites·12 claims
- 1283US9108959B2Process for the preparation of an orexin receptor antagonistBAXTER CARL A·Filed 2012·Granted Aug 18, 2015·8 cites·11 claims
- 1373US10202401B2Process for making tetracyclic heterocycle compoundsMERCK SHARP & DOHME·Filed 2017·Granted Feb 12, 2019·1 cites·3 claims
- 1461US2025082793A1Macrocyclic compounds and methods of making the sameJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 1560US2015087832A1Process for making beta 3 agonists and intermediatesMERCK SHARP & DOHME·Filed 2012·Application pending·0 cites
- 1660US2021154221A14'-substituted nucleoside reverse transcriptase inhibitors and preparations thereofMERCK SHARP & DOHME·Filed 2021·Application pending·0 cites
- 1754US12473295B2Substituted straight chain spiro derivativesJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Nov 18, 2025·0 cites·20 claims
- 1854US2024218014A1Synthesis of a cyclic peptideJANSSEN PHARMACEUTICA NV·Filed 2023·Application pending·0 cites
- 1953US2025289843A1Process for preparation of targeting ligandsARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2049US12479835B2Process for preparing 1-([3R,4S)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]pyrazole-4-carboxamideINTERVET INC·Filed 2019·Granted Nov 25, 2025·0 cites·25 claims
- 2149US7834222B2Process for the preparation of bicyclo[3.1.0]hexanolsMERCK SHARP & DOHME·Filed 2006·Granted Nov 16, 2010·0 cites·10 claims
- 2248US2025163076A1Synthesis of bruton's tyrosine kinase inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2023·Application pending·0 cites
- 2346US12018020B2Crystalline forms of 1-[(3R,4S)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]pyrazole-4-carboxamideINTERVET INC·Filed 2019·Granted Jun 25, 2024·0 cites·15 claims
- 2443US8168799B2Process for the preparation of tetrazolytetrahydrocyclopentapyrazolesASHWOOD MICHAEL STEWART·Filed 2006·Granted May 1, 2012·0 cites·12 claims
- 2543US2017166586A1Process for making tetracyclic heterocycle compoundsLI HONGMING·Filed 2015·Application pending·0 cites
- 2630US10526363B2Substituted phosphoramidate compounds and uses thereofMERCK SHARP & DOHME·Filed 2015·Granted Jan 7, 2020·0 cites·8 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →